FDA Chief Scientist Steven Kozlowski said the agency plans to include aging and longevity among topics highlighted in an updated Focus Areas of Regulatory Science (FARS) report. Kozlowski discussed the direction at the Aging Research & Drug Discovery Meeting (ARDD 2026) at Harvard, and he said the revision is due early in fiscal year 2027. The FDA’s framing centers on quantifying biological aging and establishing pre-competitive, qualified endpoints that could be used broadly across trial programs. Acting Chief of Staff Lowell M. Zeta said longevity and healthspan are important for FDA and HHS, calling the moment an inflection point for regulatory adaptation. The move signals that regulators are beginning to formalize how they may evaluate therapies aimed at biological aging mechanisms, which could shape future trial designs and endpoint strategy across the industry.